Author

C. E. Mire

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Bukreyev· 2 shared A. Carfi· 2 shared I. Ramos· 2 shared M. Meyer· 2 shared A. A. Wilson· 1 shared A. B. Rubenstein· 1 shared A. Cadete· 1 shared A. Cupic· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Bukreyev

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection

G. Baldeon Vaca, M. Meyer, A. Cadete, C. J. Hsiao, A. Golding, A. Jeon, E. Jacquinet, E. Azcue, C. M. Guan, X. Sanchez-Felix, C. A. Pietzsch, C. E. Mire, M. A. Hyde, M. E. Comeaux, J. M. Williams, , K. Bahl

This study shows intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 by inducing antibodies and reducing viral load and lung damage.

bioRxiv · Jan 11, 2023 · PreprintImmunology

The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters

L. Miorin, C. E. Mire, S. Ranjbar, A. J. Hume, J. Huang, N. A. Crossland, K. M. White, M. Laporte, T. Kehrer, V. Haridas, E. Moreno, A. Nambu, S. Jangra, A. Cupic, M. Dejosez, , A. E. Goldfeld

The paper shows that nitazoxanide inhibits SARS-CoV-2 replication and pathogenesis in human and hamster models, and synergizes with remdesivir against multiple variants.

bioRxiv · Feb 8, 2022 · PreprintImmunology

mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge

M. Meyer, Y. Wang, D. Edwards, G. R. Smith, A. B. Rubenstein, P. Ramanathan, C. E. Mire, C. Pietzsch, X. Chen, Y. Ge, W. S. Cheng, C. Henry, A. Woods, L. Ma, G. B. E. Stewart-Jones, , A. Bukreyev

This study evaluates mRNA-1273 vaccine efficacy in hamsters, showing reduced pulmonary immune activation and improved disease outcomes after prime-boost vaccination.

bioRxiv · Jan 25, 2021 · PreprintImmunology

Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates

Z. A. Bornholdt, A. S. Herbert, C. E. Mire, S. He, R. W. Cross, A. Z. Wec, D. M. Abelson, J. B. Geisbert, R. M. James, M. N. Rahim, W. Zhu, V. Borisevich, L. Banadyga, B. M. Gunn, K. N. Agans, , J. M. Dye

This paper demonstrates that a two-antibody cocktail (MBP134AF) provides broad therapeutic protection against multiple ebolaviruses in ferrets and nonhuman primates.

bioRxiv · Aug 19, 2018Microbiology